Table 2

ROC curve analysis for validation of serum AAR, APRI, FIB-4, FI, API, Pohl score and FCI for F3 and F4 in 1898 patients with HCV infection

StageCut-off valueSpecificity (%)Sensitivity (%)AUC
AAR
 F0–F3<141.962.50.377
 F4>137.662.80.412
APRI
 F0–F3<0.568.056.20.54
 F4>1.587.674.80.864
FIB-4
 F0–F3<1.4565.4510.521
 F4>3.2572.353.20.801
FI
 F0–F3<2.134.482.20.556
 F4>3.392.378.10.826
API
 F0–F3<2.558.4700.624
 F4>2.56078.10.578
Pohl score
 F0–F3058.4300.499
 F4178.138.10.599
FCI
 F0–F3<0.13157.4370.499
 F4>1.2588.178.10.867
  • AAR, AST to ALT ratio; ALT, alanine transaminase; API, Age-Platelet Index; APRI, AST to Platelet Ratio Index; AST, aspartate transaminase; AUC, area under the curve; FCI, Fibrosis Cirrhosis Index; FI, Fibrosis Index; FIB-4, fibrosis-4; HCV, hepatitis C virus; ROC curve, receiver operating characteristic curve.